AstraZeneca, FluMist
FDA approves a first-of-a-kind flu vaccine in the form of a nasal spray!
In a first, the Food and Drug Administration on Friday approved AstraZeneca's FluMist, a nasal spray flu vaccine that anyone can self-administer.
AstraZeneca FluMist gets USFDA nod for self-administered influenza vaccine
AstraZeneca has announced that FluMist has been approved in the US as the self-administered influenza vaccine. FluMist, a needle-free nasal spray, was approved to be self-administered by adults
No doctor necessary: US okays nasal spray flu vaccine for self-use
No doctor? No problem. In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was authorized in 2003 to be administered by a health care provider, will be available to ordinary Americans through an online pharmacy.
US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca (NASDAQ: AZN )'s nasal spray flu vaccine for self-administration, making it the first of its kind. FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the regulator said.
AstraZeneca PLC: FluMist approved for self-administration in US
FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist
FiercePharma13d
AstraZeneca's Alexion loses $130M to Syntimmune shareholders in post-merger payment suit
When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...
GlobalData on MSN11d
AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients
Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...
STAT6d
Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...
FiercePharma4d
AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Nucala gained nods from the FDA to treat ...
ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting
ADAURA Trail Results Reveal 79% Reduction in Risk of Death with Tagrisso The eagerly anticipated data from the Phase III ADAURA trial were announced on Sunday 31 May at the virtual ASCO 2020 ...